Macquarie Group LTD Myovant Sciences Ltd. Transaction History

Macquarie Group LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $2,969 - $5,232	-256 Reduced 9.28%	2,502 $50,000
Q4 2021 Feb 11, 2022	SELL	$14.31 - $23.87 $24,756 - $41,295	-1,730 Reduced 38.55%	2,758 $43,000
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $47,387 - $67,528	2,502 Added 125.98%	4,488 $101,000
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $22,071 - $31,756	1,293 Added 186.58%	1,986 $45,000
Q1 2021 May 14, 2021	BUY	$20.46 - $25.18 $14,178 - $17,449	693 New	693 $14,000
Q4 2020 Feb 16, 2021	SELL	$13.8 - $27.62 $14,089 - $28,200	-1,021 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$7.34 - $20.84 $7,494 - $21,277	1,021 New	1,021 $21,000
Q1 2019 May 15, 2019	SELL	$16.83 - $24.45 $2,945 - $4,278	-175 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$15.01 - $25.2 $375 - $630	-25 Reduced 12.5%	175 $3,000
Q3 2018 Nov 15, 2018	BUY	$19.33 - $26.78 $3,865 - $5,356	200 New	200 $5,000
Q1 2018 May 11, 2018	SELL	$12.46 - $21.32 $7,476 - $12,792	-600 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$11.37 - $16.4 $6,821 - $9,840	600	600 $8,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.